View Post

Rare Patient Voice: Study Opportunity for Lung Cancer Patients – African American / Ages 50 – 75

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! …

View Post

Rare Patient Voice: Study Opportunity for Prostate, Lung & Blood Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 25 minute Online Survey Compensation $45 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! Why …

View Post

Rare Patient Voice: Study Opportunity for Multiple Cancer Types

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: Cancer patients with any of the following cancer types: Breast Prostate Skin (Melanoma and Basal Cell) Bladder Kidney Lung 60 min Online Bulletin Board US patients only Compensation $100 Please sign up at the link below for more information or to see if you qualify. http://letlife.in/rare-patient-voice Why Sign up with Rare Patient Voice? Who knows better than you …

View Post

Lung Screening Bus Brings High-Tech Health Care Directly to Patients

In In The News by Barbara Jacoby

Source: The Society of Thoracic Surgeons From: prnewswire.com First-of-Its-Kind Vehicle Helps Diagnose Lung Cancer and Incidental Heart Disease A mobile platform for lung cancer screening with low-dose computed tomography (CT) can be developed with limited financial risk and take powerful screening tests directly to patients, including underserved rural areas where rates of new lung cancer cases tend to be higher, …

View Post

FDA Approves Novartis’ Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com The US Food and Drug Administration on Wednesday approved capmatinib (Novartis’ Tabrecta) for treatment of patients with metastatic non-small cell lung cancer. The agency also approved Foundation Medicine’s FoundationOne CDx assay, a broad comprehensive genomic profiling test for solid tumors, as a companion diagnostic for the drug. A companion diagnostic for capmatinib with Foundation’s liquid …

View Post

Breast Cancer and Atrial Fibrillation

In In The News by Barbara Jacoby

By: Kayla Matthews From: news-medical.net Atrial fibrillation (AFib) is a common heart rhythm problem whereby the heart’s two upper chambers, the atria, squeeze out of sync and often rapidly. This causes the heart’s walls to quiver. Numerous factors, such as age, high blood pressure, overactive thyroid, and viral infections can put people at a higher risk for developing atrial fibrillation. …

View Post

Janssen Pharmaceutical Bispecific Antibody Granted Breakthrough Designation for Lung Cancer Treatment

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Janssen Pharmaceutical Companies, a unit of Johnson & Johnson, said on Tuesday that its investigational drug JNJ-61186372 (JNJ-6372) has been granted breakthrough therapy designation by the US Food and Drug Administration. The drug is being evaluated in non-small cell lung cancer patients with EGFR exon 20 insertion mutations whose disease has progressed on or after …

View Post

Immune discovery ‘may treat all cancer’

In In The News by Barbara Jacoby

By: James Gallagher From: bbc.com A newly-discovered part of our immune system could be harnessed to treat all cancers, say scientists. The Cardiff University team discovered a method of killing prostate, breast, lung and other cancers in lab tests. The findings, published in Nature Immunology, have not been tested in patients, but the researchers say they have “enormous potential”. Experts …

View Post

Inivata to Employ Liquid Biopsy Test in EORTC Phase II NSCLC Study of Lorlatinib

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Liquid biopsy firm Inivata said today that it is collaborating with the European Organization for Research and Treatment of Cancer, using its InVisionFirst-Lung test in a Pfizer-funded Phase II trial to test lung cancer patients under treatment with the ALK inhibitor lorlatinib (marketed as Lorbrena). Investigators hope that this will help better define resistance mechanisms …

View Post

Can solar technology kill cancer cells?

In In The News by Barbara Jacoby

Source: Michigan State University From: sciencedaily.com Scientists have revealed a new way to detect and attack cancer cells using technology traditionally reserved for solar power. The results showcases dramatic improvements in light-activated fluorescent dyes for disease diagnosis, image-guided surgery and site-specific tumor treatment. Scientific breakthroughs don’t always happen in labs. For Sophia and Richard Lunt, Michigan State University researchers, many …